Jpmorgan Chase & CO Poseida Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PSTX
# of Institutions
94Shares Held
38.2MCall Options Held
417KPut Options Held
42.7K-
Pentwater Capital Management LP Naples, FL5.98MShares$15.1 Million0.23% of portfolio
-
Black Rock Inc. New York, NY4.91MShares$12.4 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA4.48MShares$11.3 Million0.73% of portfolio
-
Silverarc Capital Management, LLC3.61MShares$9.13 Million2.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.41MShares$8.62 Million0.0% of portfolio
About Poseida Therapeutics, Inc.
- Ticker PSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 85,775,600
- Market Cap $217M
- Description
- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...